Related Experiment Video

Updated: May 20, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense

Alessio Aghemo1, Pietro Lampertico, Massimo Colombo

  • 1Department of Medicine, A.M. Migliavacca Center for Liver Diseases and First Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

Journal of Hepatology
|July 4, 2012
PubMed

Insights

Chronic hepatitis B and C infections affect millions globally. Surrogate endpoints are used to assess antiviral therapy efficacy due to the slow disease progression, but their reliability needs validation.

Area of Science:

  • Hepatology and Viral Immunology
  • Clinical Pharmacology

Background:

  • Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are significant global health issues, affecting approximately 400 million and 200 million people, respectively.
  • Assessing the long-term efficacy of antiviral therapies for these chronic viral infections is challenging due to their slow disease progression over decades.

Purpose of the Study:

  • To evaluate the necessity and reliability of surrogate endpoints in assessing the efficacy of antiviral treatments for chronic hepatitis B and C.
  • To determine if surrogate endpoints adequately predict long-term patient survival and reduction in liver-related complications.

Main Methods:

  • Review of existing clinical trial designs and outcomes for antiviral therapies targeting chronic HBV and HCV.
  • Analysis of the correlation between established surrogate endpoints and definitive clinical outcomes (survival, liver complications).
  • Examination of regulatory guidelines and clinical practice standards regarding the use of surrogate endpoints.

Main Results:

  • Surrogate endpoints allow for faster evaluation of therapeutic interventions, facilitating quicker access to new drugs and healthcare innovations.
  • The slow natural history of chronic viral hepatitis complicates the direct measurement of long-term clinical benefits.
  • A critical need exists to validate that chosen surrogate endpoints are robust predictors of actual patient outcomes.

Conclusions:

  • Surrogate endpoints are currently indispensable for standardizing and accelerating the evaluation of antiviral therapies for chronic hepatitis B and C.
  • Further research and rigorous validation are essential to ensure that surrogate endpoints reliably reflect long-term patient survival and disease mitigation.
  • Establishing the predictive value of surrogate endpoints is crucial for informed clinical decision-making and healthcare policy.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...